Matthew L. Kaplan is Director at Nuvectis Pharma, Inc. (NVCT). They have made 2 open-market trades across 1 company since 2022, most recently 2026-06-11.
CIK 0001895952
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $115K since 2022, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NVCT | 159,760 | $2.9M |
Shares reported on the most recent Form 4, priced at the 2026-06-12 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.